Larimar Therapeutics reports Q4, full year 2025 results

Larimar Therapeutics has released its financial results for the fourth quarter and the full year 2025. The company also noted that its drug nomlabofusp has received Breakthrough Therapy Designation from the FDA for treating Friedreich's Ataxia (FA) in adults and children. This designation is based on the FDA's review of available clinical data, indicating significant potential for the therapy. The positive clinical development, coupled with the financial reporting, suggests a period of progress and potential growth for Larimar Therapeutics in the biotechnology sector.